Additional ACG presentation to underscore the significance of Xifaxan in reducing OHE rehospitalizations
LAVAL, QC / ACCESSWIRE / October 27, 2024 / Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC), along with its gastroenterology sector, Salix Pharmaceuticals (“Salix”), has announced a pivotal analysis on the effects of Xifaxan® (rifaximin) monotherapy, which will be showcased during a Presidential Plenary Session at The American College of Gastroenterology® (ACG) 2024 Annual Scientific Meeting. This notable event is being held from October 25 to 30 in Philadelphia, PA. The post hoc analysis delves into the comparative effectiveness of Xifaxan monotherapy versus lactulose monotherapy, particularly focusing on the reduction of recurrence risk for overt hepatic encephalopathy (OHE) and the overall mortality rate.
During ACG 2024, Salix is poised to unveil fresh insights regarding the influence of Xifaxan on rehospitalization rates for patients discharged after an OHE hospitalization—this data spans both commercially insured and Medicare patient demographics. The findings are anticipated to further substantiate the clinical benefits of Xifaxan in managing the complexities of OHE.
In addition, two informative posters at the ACG conference will highlight research results involving Plenvu® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride, and potassium chloride for oral solution) as an efficient bowel preparation agent, shedding light on efficacy outcomes from colonoscopy patients who are either dealing with comorbidities or taking other medications known to affect bowel preparation effectiveness.
“These presentations at ACG 2024 can provide healthcare professionals with critical insights, reinforcing that Salix treatments are highly effective at improving patient outcomes,” remarked Aimee Lenar, Executive Vice President of US Pharma at Bausch Health. “Our unwavering commitment at Bausch Health towards life-altering healthcare solutions is evident as we continuously invest in expanding the evidential base for our medicinal products both today and into the future.”
The comprehensive list of Salix research and analyses set for presentation at ACG 2024 includes:
XIFAXAN
-
Bajaj, Jasmohan S. et.al. Rifaximin Monotherapy Is More Effective Than Lactulose Monotherapy for Reducing the Risk of Overt Hepatic Encephalopathy (OHE) Recurrence and All-Cause Mortality: An Analysis of Two Randomized Trials.
-
Presidential Plenary Session 2; Presentation #9
-
Monday, October 28, 10:06 – 10:18 AM ET
-
-
Jesudian, Arun B. et.al. Impact of Rifaximin Use on Overt Hepatic Encephalopathy (OHE) Rehospitalizations Post Discharge from an OHE Hospitalization in Commercially and Medicare Insured Patients.
PLENVU
-
Cash, Brooks D. et.al. Efficacy and Safety of the 1 Liter NER1006 Bowel Preparation for Colonoscopy in Adults With Comorbid Conditions That May Impact Prep Quality.
-
Poppers, David. et.al. One-Liter NER1006 Is Efficacious as a Bowel Preparation for Colonoscopy in Patients Taking Concomitant Medications Known to Impact Prep Quality.
About XIFAXAN
INDICATION
XIFAXAN® (rifaximin) 550 mg tablets are indicated for the reduction in risk of overt hepatic encephalopathy (HE) recurrence in adults and for the treatment of irritable bowel syndrome with diarrhea (IBS-D) in adults.
IMPORTANT SAFETY INFORMATION
-
XIFAXAN is contraindicated in patients with a hypersensitivity to rifaximin, rifamycin antimicrobial agents, or any of the components in XIFAXAN.
-
Clostridium difficile-associated diarrhea (CDAD) has been reported with use of nearly all antibacterial agents, including XIFAXAN, and may range in severity from mild diarrhea to fatal colitis.
-
There is an increased systemic exposure in patients with severe (Child-Pugh Class C) hepatic impairment.
-
Caution should be exercised when concomitant use of XIFAXAN and P-glycoprotein (P-gp) and/or OATPs inhibitors is needed.
-
In clinical studies, the most common adverse reactions for XIFAXAN (alone or in combination with lactulose) were:
-
HE (=10%): Peripheral edema (17%), constipation (16%), nausea (15%), fatigue (14%), insomnia (14%), ascites (13%), dizziness (13%), urinary tract infection (12%), anemia (10%), and pruritus (10%).
-
IBS-D (=2%): Nausea (3%), ALT increased (2%).
To report SUSPECTED ADVERSE REACTIONS, contact Salix Pharmaceuticals at 1-800-321-4576 or FDA at 1-800-FDA-1088 or www.fda.gov/medwatch.
Please click here for full Prescribing Information.
About PLENVU
INDICATION
PLENVU® (polyethylene glycol 3350, sodium ascorbate, sodium sulfate, ascorbic acid, sodium chloride, and potassium chloride for oral solution) is a prescription medication used by adults to clean the colon before a colonoscopy.
IMPORTANT SAFETY INFORMATION
-
PLENVU® and other bowel preparations can cause serious side effects including loss of body fluid (dehydration) and changes in blood salts (electrolytes) in your blood.
-
Your healthcare provider may do blood tests after you take PLENVU® to check your blood for changes.
-
PLENVU® can cause ulcers of the bowel or bowel problems (ischemic colitis).
-
PLENVU® can cause serious allergic reactions that may include skin rash, itching, or hives.
-
The most common side effects in patients taking PLENVU® were nausea, vomiting, dehydration, and stomach pain or discomfort.
These are not all the possible side effects of PLENVU®. Ask your healthcare provider for more information.
About Bausch Health
Bausch Health Companies Inc. (NYSE:BHC)(TSX:BHC) is a global diversified pharmaceutical company dedicated to enhancing lives by driving better healthcare outcomes. Our ambition is to be a globally integrated healthcare company, trusted and valued by patients, healthcare professionals, employees, and investors. For more information about Salix, visit www.Salix.com and connect with us on Twitter and LinkedIn. For more information about Bausch Health, visit www.bauschhealth.com and connect with us on LinkedIn.
###
SOURCE: Salix Pharmaceuticals
View the original press release on accesswire.com
Interview with Aimee Lenar, Executive Vice President of US Pharma at Bausch Health
Interviewer: Thank you for joining us today, Aimee. As we look back at the recent ACG 2024 Annual Scientific Meeting, can you tell us more about the significance of the findings related to Xifaxan presented there?
Aimee Lenar: Thank you for having me. We’re excited about the insights shared during ACG 2024 regarding Xifaxan® (rifaximin). The pivotal analysis highlighted that Xifaxan monotherapy is more effective than lactulose monotherapy in reducing the risk of recurrence and mortality associated with overt hepatic encephalopathy (OHE). This data is crucial as it could significantly impact patient management strategies.
Interviewer: That’s impressive! Specifically, how do these results affect rehospitalization rates for patients recovering from OHE?
Aimee Lenar: The analysis presented during the conference showed that Xifaxan has the potential to lower rehospitalization rates for patients discharged after an OHE hospitalization. This is particularly relevant for both commercially insured and Medicare patient groups. By reducing the likelihood of rehospitalization, Xifaxan not only improves patient outcomes but also alleviates the burden on healthcare systems.
Interviewer: It sounds like this research could lead to a shift in treatment practices. What do you hope healthcare professionals take away from these presentations?
Aimee Lenar: Our goal is for healthcare professionals to understand that Xifaxan is a highly effective option for managing OHE. The data presented not only reinforces the clinical benefits of our treatments but also emphasizes our commitment to improving quality of life for patients living with this condition. We want to ensure that these insights translate into better patient outcomes in clinical settings.
Interviewer: Beyond Xifaxan, I see there were also presentations involving Plenvu®. Can you briefly touch on that?
Aimee Lenar: Certainly! Plenvu® is a bowel preparation solution that has shown efficacy in patients with various comorbidities. The research presented illuminated its effectiveness even among populations that typically face challenges in bowel preparation quality. This further exemplifies Salix’s dedication to addressing the needs of diverse patient groups.
Interviewer: Thank you, Aimee, for shedding light on these important findings. It seems like Bausch Health is making significant strides in gastroenterology.
Aimee Lenar: Thank you for the opportunity to share our insights. We remain steadfast in our mission to provide evidence-based healthcare solutions that genuinely improve patient outcomes.
Aimee Lenar: We hope that healthcare professionals will be encouraged to consider Xifaxan as a first-line treatment option for managing overt hepatic encephalopathy. The insights from our research reinforce the importance of looking at the comparative effectiveness of treatments and making informed decisions to improve patient outcomes. Our goal is to ensure that patients have access to the most effective therapies available, and we believe our findings at ACG 2024 underline that commitment.
Interviewer: That’s a vital message. Are there any additional findings or discussions from ACG 2024 that you’d like to highlight?
Aimee Lenar: Yes, indeed. Alongside the Xifaxan findings, we also presented data on Plenvu® as an efficient bowel preparation agent for colonoscopy. This research focused on specific patient demographics, including those with comorbidities and those taking other medications that might complicate bowel preparation. These collective findings underscore our commitment to advancing patient care across various conditions and enhancing clinical outcomes.
Interviewer: Aimee, thank you so much for your insights today. It’s clear that the work being done by Bausch Health and Salix is making a significant impact in the gastroenterology space.
Aimee Lenar: Thank you for having me. We’re excited about the future and the opportunities to continue supporting healthcare providers and their patients with effective treatment options.
